Analyst Opinion Summary: AMERI Holdings, Inc. (AMRH), Biocept, Inc. (BIOC)

AMERI Holdings, Inc. (NASDAQ:AMRH) tinted gains of +12.89% (+0.03 points) to US$0.34. The volume of 8.35 Million shares climbed up over an trading activity of 1.34 Million shares. EPS ratio determined by looking at last 12 month figures is -0.12. Over the same time span, the stock marked US$3 as its best level and the lowest price reached was US$0.15. The corporation has a market cap of US$12.22 Million.

AMERI Holdings, Inc. (NASDAQ:AMRH)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -5.3 percent while most common profitability ratio return on investment (ROI) was -36 percent. The company’s institutional ownership is monitored at 4.6 percent. The company’s net profit margin has achieved the current level of -2.6 percent and possesses 20.6 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Biocept, Inc. (NASDAQ:BIOC) is worth US$11.38 Million and has recently fallen -0.95% to US$1.04. The latest exchange of 1.45 Million shares is below its average trading activity of 2.26 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$12.29 while the mean 12-month price target for the shares is US$5.13.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.33, and a price to sales ratio of 3.35. For the past 5 years, the company’s revenue has grown 115.4%, while the company’s earnings per share has grown 45.8%. With an institutional ownership near 12.3%, it carries an earnings per share ratio of -10.69.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.